| Name | Title | Contact Details |
|---|
Roar Biomedical is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Masonry Technology Inc is a Moreno Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TruSpine is a medical device company focused on entering the $10.2 billion (US) per annum spinal device market. The Company is developing uniquely disruptive technologies to revolutionise the spinal stabilisation market, commencing with three flagship pioneering, spinal devices. The Cervi-LOK™ (for the cervical and upper thoracic spine), GRASP Laminoplasty (a treatment for decompression of the spinal cord) & Faci-LOK™ (for the lumbar and lower thoracic spine). These unique devices represent a paradigm shift in spinal fixation, by providing exceptional stabilization while not altering the bony anatomy such as screws, staples or other devices which currently dominate the spinal market. The TruSpine philosophy and mantra is one of preserving nature`s design, and as such, the devices have been designed to be safer, faster and easier to implant. The potential cost savings to patients, insurers and surgeons can be significant. The technology is minimally intrusive, minimally invasive and reversable. The first product to market will be Cervi-LOK™, and will be the first posterior cervical stabilisation device in the world which fully preserves the boney anatomy of the spine. TruSpine has a phased product development strategy, and is planning to commence initial product marketing between late 2020 to early 2021. The overall aim is to establish the TruSpine products as the go-to solutions for the spinal stabilisation market. In addition to the three flagship platform products currently under development, the company also has a pipeline of additional and complementary spinal products.
CellMax Life is revolutionizing early cancer detection, prevention and management.
Avista Pharma Solutions is a contract development and manufacturing organization (CDMO) formed through the recent, strategic carve-outs of the CMC business of Array BioPharma, Inc. and contract services business of Scynexis, Inc. These two operations, along with the microbiology and analytical testing capabilities of the parent company Accuratus, create a combined business encompassing over 170,000 square feet of laboratory and manufacturing space which is capable of providing pharmaceutical clients with a broad suite of scientifically-differentiated services. These services are provided from a team with demonstrated expertise in process chemistry, analytical chemistry, manufacturing of novel drugs and specialized animal health services.